BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, has announced an upcoming oral presentation at the Society for Melanoma Research 21st International Congress (SMR) in New Orleans, LA, from October 10–13, 2024.
The presentation details are as follows:
- Title: Evalstotug (BA3071): a potent conditionally active biologic (CAB) anti-CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicity
- Presenting Author: William Boyle, Ph.D.
- Session Category: Developmental Immunotherapy
- Date & Time: Friday, October 11th, 2024 from 8:00am–10:20am CDT
The abstract will be published in the 2024 SMR Abstract book and online in the PCMR journal. Presentation materials will be available on BioAtla's website after the presentation concludes.
BioAtla, Inc. (Nasdaq: BCAB), una società biotecnologica globale in fase clinica focalizzata sullo sviluppo di terapeutiche a base di anticorpi Conditionally Active Biologic (CAB) per i tumori solidi, ha annunciato una prossima presentazione orale al 21° Congresso Internazionale della Society for Melanoma Research (SMR) a New Orleans, LA, dal 10 al 13 ottobre 2024.
Dettagli della presentazione sono i seguenti:
- Titolo: Evalstotug (BA3071): un potente anticorpo anti-CTLA-4 biologico attivo condizionalmente (CAB) progettato per consentire elevate esposizioni, dosaggi prolungati e ridotta tossicità immuno-mediata
- Autore Presentatore: William Boyle, Ph.D.
- Categoria della Sessione: Immunoterapia Sviluppativa
- Data e Ora: Venerdì 11 ottobre 2024 dalle 8:00 alle 10:20 CDT
L'abstract sarà pubblicato nel libro degli abstract SMR 2024 e online nella rivista PCMR. I materiali della presentazione saranno disponibili sul sito web di BioAtla dopo la conclusione della presentazione.
BioAtla, Inc. (Nasdaq: BCAB), una compañía biotecnológica global en etapa clínica que se centra en el desarrollo de terapias con anticuerpos Conditionally Active Biologic (CAB) para tumores sólidos, ha anunciado una próxima presentación oral en el 21° Congreso Internacional de la Society for Melanoma Research (SMR) en Nueva Orleans, LA, del 10 al 13 de octubre de 2024.
Los detalles de la presentación son los siguientes:
- Título: Evalstotug (BA3071): un potente anticuerpo anti-CTLA-4 biológico activo condicionalmente (CAB) diseñado para permitir altas exposiciones, dosificaciones prolongadas y reducción de la toxicidad mediada por el sistema inmunológico
- Autor Presentador: William Boyle, Ph.D.
- Categoría de Sesión: Inmunoterapia en Desarrollo
- Fecha y Hora: Viernes, 11 de octubre de 2024, de 8:00 a 10:20 CDT
El resumen se publicará en el libro de resúmenes de SMR 2024 y en línea en la revista PCMR. El material de la presentación estará disponible en el sitio web de BioAtla después de que concluya la presentación.
BioAtla, Inc. (Nasdaq: BCAB), 고형 종양을 위한 조건부 활성 생물학(CAB) 항체 치료제를 개발하는 데 초점을 맞춘 글로벌 임상 단계 생명공학 회사가 2024년 10월 10일부터 13일까지 미국 뉴올리언스에서 열리는 제21회 흑색종 연구 협회(SMR) 국제 회의에서 구두 발표를 진행한다고 발표했습니다.
발표 세부 사항은 다음과 같습니다:
- 제목: Evalstotug (BA3071): 높은 노출, 연장된 용량 및 면역 매개 독성을 줄이도록 설계된 강력한 조건부 활성 생물학(CAB) 항체 항-CTLA-4
- 발표 저자: 윌리엄 보일, Ph.D.
- 세션 카테고리: 개발 면역 요법
- 날짜 및 시간: 2024년 10월 11일 금요일, 오전 8:00 – 오전 10:20 CDT
초록은 2024 SMR 초록집에 게재되며, PCMR 저널 온라인에서도 확인할 수 있습니다. 발표 자료는 발표가 끝난 후 BioAtla 웹사이트에서 확인할 수 있습니다.
BioAtla, Inc. (Nasdaq: BCAB), une entreprise biopharmaceutique mondiale en phase clinique axée sur le développement de thérapies anticorps biologiques activés de manière conditionnelle (CAB) pour les tumeurs solides, a annoncé une prochaine présentation orale lors du 21e Congrès international de la Society for Melanoma Research (SMR) à La Nouvelle-Orléans, LA, du 10 au 13 octobre 2024.
Les détails de la présentation sont les suivants :
- Titre : Evalstotug (BA3071) : un puissant anticorps anti-CTLA-4 biologique activé de manière conditionnelle (CAB) conçu pour permettre de fortes expositions, un dosage prolongé et réduire la toxicité médiée par le système immunitaire
- Auteur de la présentation : William Boyle, Ph.D.
- Catégorie de session : Immunothérapie de développement
- Date et heure : Vendredi 11 octobre 2024 de 8h00 à 10h20 CDT
Le résumé sera publié dans le livre des résumés SMR 2024 et en ligne dans la revue PCMR. Les documents de présentation seront disponibles sur le site Web de BioAtla après la conclusion de la présentation.
BioAtla, Inc. (Nasdaq: BCAB), ein globales biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von bedingt aktiven biologischen (CAB) Antikörpertherapeutika für solide Tumoren konzentriert, hat eine bevorstehende mündliche Präsentation auf dem 21. Internationalen Kongress der Society for Melanoma Research (SMR) in New Orleans, LA, vom 10. bis 13. Oktober 2024 angekündigt.
Die Einzelheiten der Präsentation sind wie folgt:
- Titel: Evalstotug (BA3071): ein potentes, bedingt aktives biologisches (CAB) Anti-CTLA-4-Antikörper, das hohe Expositionen, verlängerte Dosierung und reduzierte immunvermittelte Toxizität ermöglicht
- Präsentierender Autor: William Boyle, Ph.D.
- Sitzungskategorie: Entwicklung immuntherapie
- Datum & Uhrzeit: Freitag, 11. Oktober 2024, von 8:00 bis 10:20 Uhr CDT
Das Abstract wird im Abstract-Buch der SMR 2024 sowie online in der PCMR-Zeitschrift veröffentlicht. Die Präsentationsmaterialien sind nach Abschluss der Präsentation auf der Website von BioAtla verfügbar.
- Acceptance of abstract for oral presentation at a major industry conference (SMR)
- Opportunity to showcase Evalstotug (BA3071), a potentially innovative anti-CTLA-4 antibody
- None.
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced acceptance of an abstract for oral presentation at the upcoming Society for Melanoma Research 21st International Congress (SMR), being held from October 10–13, 2024, in New Orleans, LA.
Oral Presentation Details:
Abstract title: | Evalstotug (BA3071): a potent conditionally active biologic (CAB) anti-CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicity |
Presenting Author: | William Boyle, Ph.D. |
Abstract Type: | Oral |
Session Category: | Developmental Immunotherapy |
Date & Time: | Friday, October 11th, 2024 from 8:00am–10:20am CDT |
The accepted abstract will be published in the 2024 SMR Abstract book in electronic format, as well as published online in the PCMR journal at www.wiley.com. Additionally, a copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 765 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
What is the title of BioAtla's presentation at the SMR 21st International Congress?
When and where will BioAtla (BCAB) present at the SMR 21st International Congress?
Who is presenting BioAtla's (BCAB) research at the SMR 21st International Congress?